Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying and developing novel treatments for rare diseases and diseases caused by multi-drug resistant (MDR) bacterial infections with unmet need. Its product candidate SPR720 is an investigational, chemically stable phosphate ester prodrug that is converted in vivo to SPR719 for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease. Its clinical stage product candidate, tebipenem HBr is an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTIs) including acute pyelonephritis (AP) to help patients potentially reduce duration of in-patient therapy.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
30/06/26	US$2.210	-2.21%	435,192
29/06/26	US$2.260	-.--%	518,253
26/06/26	US$2.260	+11.88%	2,222,022
25/06/26	US$2.020	-3.81%	1,146,404
24/06/26	US$2.100	-2.33%	893,780

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

2.210USD

Average target price

4.000USD

Spread / Average Target

+81.00%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 21:00:00 30/06/2026 BST			5-day change	1st Jan Change
2.210 ^USD	-2.21%		+2.79%	-5.15%

06-29	Spero Therapeutics, Inc.(NasdaqGS:SPRO) added to Russell 3000E Growth Benchmark	CI
06-29	Spero Therapeutics, Inc.(NasdaqGS:SPRO) added to Russell 3000E Index	CI

Market Cap	128M 112M 103M 96.45M 182M 12.1B 185M 1.24B 481M 5.97B 481M 470M 20.8B	P/E 2024	-0.81x	P/E 2025	15.5x
Enterprise Value	128M 112M 103M 96.45M 182M 12.1B 185M 1.24B 481M 5.97B 481M 470M 20.8B	EV / Sales 2024	1,170,430x	EV / Sales 2025	-
Free-Float	77.61%	Yield 2024 *	-	Yield 2025	-

06-29	Spero Therapeutics, Inc.(NasdaqGS:SPRO) added to Russell 3000E Growth Benchmark	CI
06-29	Spero Therapeutics, Inc.(NasdaqGS:SPRO) added to Russell 3000E Index	CI
06-29	Spero Therapeutics, Inc.(NasdaqGS:SPRO) added to Russell Microcap Index	CI
06-28	Spero Therapeutics, Inc.(NasdaqGS:SPRO) added to Russell Microcap Growth Benchmark Index	CI
06-17	GSK says US FDA approves urinary tract infection treatment Utebzi	AN
06-17	GSK plc Receives US FDA Approval for Oral Antibiotic Tebipenem for Complicated Urinary Tract Infections	CI
06-17	GSK Secures US FDA Nod for Complicated Urinary Tract Infection Antibiotic	MT
06-17	GSK, Spero Therapeutics Get FDA Approval for Utebzi in Complicated Urinary Tract Infections	MT
06-17	GSK, Spero Therapeutics Gain U.S. Approval for Utebzi	DJ
06-17	US FDA approves GSK's oral antibiotic for drug-resistant UTIs	RE
05-13	Spero Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
03-26	Spero Therapeutics Q4 Swings to Profit, Revenue Rises	MT
03-26	Spero Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI

21/10/25	Spero Therapeutics, Inc. and Gsk plc Announces Efficacy and Safety Results of the Positive Pivot-Po Trial Evaluating Tebipenem Hbr	CI
20/12/24	Evercore ISI Downgrades Spero Therapeutics to In Line From Outperform, Price Target is $5	MT
18/11/24	TD Cowen Downgrades Spero Therapeutics to Hold From Buy	MT
06/08/24	TD Cowen Upgrades Spero Therapeutics to Buy From Hold	MT
14/08/23	HC Wainwright Adjusts Price Target on Spero Therapeutics to $7 From $6, Keeps Buy Rating	MT

Spero Therapeutics, Inc. Share Price

Stocks

SPRO

US84833T1034

Biotechnology & Medical Research

Valuation: Spero Therapeutics, Inc.

Chart: Spero Therapeutics, Inc.

Latest news : Spero Therapeutics, Inc.

Last Transcript: Spero Therapeutics, Inc.

Analysts' recommendations: Spero Therapeutics, Inc.

Press Releases: Spero Therapeutics, Inc.

News in other languages: Spero Therapeutics, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Spero Therapeutics, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

05-13	Spero Therapeutics Announces First Quarter 2026 Operating Results and Provides Business Update	AQ
05-05	Spero Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026	AQ
03-26	Spero Therapeutics Announces Fourth Quarter and Full Year 2025 Operating Results and Provides a Business Update	AQ
03-18	Spero Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 26, 2026	AQ
01-30	SEC Enforcement Action Against Former Spero Executives: Individual Liability For Misleading FDA-Related Disclosures	AQ

06-18	Bourse : L'Oréal met le cap sur l'Inde, gros contrat pour Alstom, rumeur sur Edenred
06-18	Star Warsh
06-18	MORNING BRIEFING - Deutschland/Europa -2-
06-17	GSK und Spero Therapeutics erhalten US-Zulassung für Utebzi
21/10/25	GSK et Spero publient des résultats positifs sur un antibiotique expérimental

1 day	-2.21%
1 week	+2.79%
1 month	-21.91%
3 months	-5.56%
6 months	-5.15%
Current year	-5.15%

1 week	2.01	2.33
1 month	1.95	3.07
Current year	1.95	3.08
1 year	1.8	3.22
3 years	0.51	3.22
5 years	0.51	19.87
10 years	0.51	23.64

Manager	Title	Age	Since
Esther Rajavelu CEO	Chief Executive Officer	47	09/01/2025
Timothy Keutzer COO	Chief Operating Officer	58	31/01/2023
Shai Biran IRC	Investor Relations Contact	-	-

Director	Title	Age	Since
Milind Deshpande CHM	Chairman	69	31/12/2013
Patrick Volkert Vink BRD	Director/Board Member	62	31/08/2015
Frank Thomas CHM	Chairman	56	09/01/2025

Date	Insider	Type	Main position	Quantity	% Market Cap.
06-22	Scott Jackson	Free	Director	30,000	0.0518%
06-22	John Pottage	Free	Director	30,000	0.0518%
06-22	Milind Deshpande	Free	Director	30,000	0.0518%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SPERO THERAPEUTICS, INC.	-2.21%	+2.79%	-23.79%	+52.41%	128M
ARGENX SE	+0.02%	+8.42%	+70.68%	+132.28%	57.65B
WUXI APPTEC CO., LTD.	-1.32%	+17.12%	+79.02%	+99.82%	55.14B
BIONTECH SE	-1.28%	+2.68%	-12.60%	-13.79%	23.53B
INSMED INCORPORATED	+1.79%	+4.38%	+5.94%	+405.31%	23.11B
WUXI BIOLOGICS (CAYMAN) INC.	-1.93%	+11.11%	+34.89%	-7.86%	18.14B
GENMAB A/S	0.00%	+5.30%	+36.67%	-30.72%	16.84B
EXELIXIS, INC.	+0.24%	+5.98%	+23.45%	+184.72%	13.68B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+0.14%	+9.60%	+33.31%	-	12.97B
MADRIGAL PHARMACEUTICALS, INC.	+1.83%	+4.58%	+77.42%	+132.45%	12.38B
Average	-0.27%	+5.39%	+32.50%	+106.07%	23.36B
Weighted average by Cap.	-0.29%	+4.87%	+48.09%	+116.44%

	2024	2025
Net sales	47.98M 41.99M 38.77M 36.16M 68.13M 4.54B 69.35M 465M 181M 2.24B 180M 176M 7.8B	66.8M 58.47M 53.98M 50.35M 94.87M 6.32B 96.56M 647M 251M 3.12B 251M 245M 10.86B
Net income	-68.57M -60.02M -55.4M -51.68M -97.37M -6.48B -99.11M -665M -258M -3.2B -258M -252M -11.15B	8.57M 7.5M 6.93M 6.46M 12.17M 810M 12.39M 83.08M 32.25M 400M 32.21M 31.49M 1.39B
Net Debt	-	-